What is the treatment for Staphylococcus (Staph) infections?

Treatment of Staphylococcus (Staph) Infections

The treatment of Staphylococcus aureus infections requires targeted antimicrobial therapy based on methicillin susceptibility, with penicillinase-resistant penicillins being first-line for methicillin-susceptible S. aureus (MSSA) and vancomycin for methicillin-resistant S. aureus (MRSA). 1

Initial Approach to Staph Infections

• Obtain cultures from the infection site before starting antibiotics to confirm S. aureus and determine antimicrobial susceptibility 2
• Repeat blood cultures at 2-4 days after initial positive cultures to document clearance of bacteremia in cases of S. aureus bacteremia 2
• Perform thorough source control including drainage of abscesses, removal of infected catheters, and debridement of infected tissue 2

Antibiotic Selection Based on Methicillin Susceptibility

For MSSA Infections:

• First-line therapy: Penicillinase-resistant penicillins (flucloxacillin, dicloxacillin) remain the antibiotics of choice 1
  • Dicloxacillin dosing: 125-250 mg every 6 hours for mild to moderate infections; 250 mg every 6 hours for severe infections 3
• Alternative options for less serious infections or penicillin-allergic patients:
  • First-generation cephalosporins (cefazolin, cephalexin) 1
  • Clindamycin (if local resistance rates <10%) 2
  • Note: Cephalosporins are contraindicated in patients with immediate penicillin hypersensitivity 1

For MRSA Infections:

• Serious infections: Vancomycin IV is the first-line treatment 2
  • Dosing: 15-20 mg/kg/dose every 8-12 hours, not exceeding 2 g per dose 2
  • Target trough concentrations: 15-20 μg/mL for serious infections 2
• Outpatient/oral options for skin and soft tissue infections:
  • Clindamycin (600 mg PO three times daily) if local resistance rates <10% 2
  • Trimethoprim-sulfamethoxazole (TMP-SMX) 2
  • Tetracyclines (doxycycline or minocycline) 2
  • Linezolid (600 mg twice daily) 2

Treatment Duration

• Uncomplicated skin and soft tissue infections: 5-10 days, individualized based on clinical response 2
• S. aureus bacteremia: 4-6 weeks for bacteremia with high-risk features 2
• Osteomyelitis: 6 weeks after implant removal; 12 weeks with implant retention 2

Special Considerations

Pediatric Patients:

• Vancomycin is recommended for hospitalized children with serious MRSA infections 2
• Clindamycin 10-13 mg/kg/dose IV every 6-8 hours (not exceeding 40 mg/kg/day) is an option if local resistance is low 2
• Tetracyclines should not be used in children <8 years of age 2

Persistent Bacteremia:

• Consider combination therapy with daptomycin plus ceftaroline for persistent S. aureus bacteremia 2
• Evaluate for metastatic foci of infection with appropriate imaging studies 2

Prevention of Recurrent Infections

• Keep draining wounds covered with clean, dry bandages 2
• Maintain good personal hygiene with regular bathing and hand cleaning 2
• Focus cleaning efforts on high-touch surfaces that may contact bare skin 2
• Consider decolonization strategies for recurrent infections:
  • Nasal mupirocin twice daily for 5-10 days 2
  • Chlorhexidine body washes or dilute bleach baths 2

Common Pitfalls to Avoid

• Failure to obtain cultures before starting antibiotics can lead to inadequate treatment 2
• Inadequate source control (not draining abscesses, not removing infected devices) 2
• Using tetracyclines in children under 8 years of age 2
• Using rifampicin or fusidic acid as single agents (rapid resistance development) 2
• Continuing broad-spectrum coverage when targeted therapy based on susceptibilities is available 2